12,372 trials
Infection
Primary: Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population — 315; 324; 37; 23 participants
Hypertension
Primary: Percentage of Participants Who Experienced Adverse Events — 77.3; 77.1 percentage of participants
Contraception
Primary: Number of Days With Bleeding Including Spotting — 41; 61; 66 days — p=<0.0001
Restless Legs Syndrome
Primary: The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS)…
Abscesses
Primary: Treatment Failures at 7 Days — 15; 27 participants
Papillomavirus Type 16/18 Infection · Cervical Intraepithelial Neoplasia
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL
Cervical Intraepithelial Neoplasia · Papillomavirus Infection
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 3901.6; 3226.3; 2688.6; 2395.8 EL.U/mL
Urinary Tract Infection
Primary: Microbiological Response Assessment Profile — 58; 63 Participants
Rheumatoid Arthritis
Primary: Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24 — 129; 131; 59 Participants — p=<0.001
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 213; 224; 21; 9 Participants — p=0.0769
HIV Infections · AIDS Virus · Human Immunodeficiency Virus
Primary: Virological Response [Per Protocol (PP) - Time to Loss of Virologic Response (TLOVR), < 50 Copies/ml, Week 48] — 108; 106 participants
Colorectal Cancer
Primary: Weekly Steady-state Exposure of Bevacizumab — 4090.3; 4022.4 day*ug/mL
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 217; 206; 14; 13 Participants — p=0.5667
Early Rheumatoid Arthritis
Primary: Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52 — 118; 113; 165 participants — p=<0.001
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL — 741; 383; 124 Participants